by Mark Curtis | Jan 13, 2014
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....
by Mark Curtis | Nov 27, 2013
. Welcome to the regenerative medicine deal review for the month of November. Cytori Therapeutics and Lorem Vascular have teamed up to catalyze the commercialization of Cytori cell therapies using its proprietary Celution® System in Asia. There was also a notable deal...
by Mark Curtis | Oct 17, 2013
. Welcome to the first Regenerative Medicine Deal Review, an overview of recent licensing, partnering, and financing activity all exclusively in the regenerative medicine and cell therapy industries. Like my first post ‘Update from the Clinic’, this piece is intended...
by Mark Curtis | Oct 3, 2013
. I have recently joined the business development group at CCRM, as an analyst, and believe it would be useful to start compiling some recaps on clinical developments in the regenerative medicine (RM) and cell therapy industries to complement the other science-related...
by David Brindley | Jun 14, 2013
. The sheer scale of ISSCR 2013, which has attracted almost four thousand delegates, and the proficiency with which it is run, is a major achievement by its organizer and lead sponsor: the International Society for Stem Cell Research and the Harvard Stem Cell...
Comments